Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Synta Pharmaceuticals
Biotech
Madrigal says NASH drug also works in cholesterol disorder
Madrigal Pharma is celebrating after its lead drug, MGL-3196, hit the mark in a phase 2 trial in the second of its two target indications: heterozygous familial hypercholesterolemia.
Phil Taylor
Feb 8, 2018 10:36am
Madrigal’s NASH drug hits liver fat in midstage test
Dec 6, 2017 7:47am
After PhIII failure Synta announces merger, shifts R&D focus
Apr 14, 2016 9:53am
Synta Pharmaceuticals Reports Third-Quarter 2010 Financial Results and Clinical Update
Nov 4, 2010 8:23am